BlinkLab (ASX: BB1)
Healthcare & Biotechnology
ADHD Breakthrough Expands the Opportunity | Autism Dx1 Advances Towards FDA Approval
We are revising our target price for BlinkLab (ASX: BB1) upward to $3.06, implying a compelling 354% total upside from the current $0.68 share price and marking an uplift of 29% from our November 2025 Update report. Our revised valuation reflects material progress across both of BlinkLab’s core programmes. Dx1, its lead Autism Spectrum Disorder (ASD) diagnostic, has progressed from a successful US Pilot Study into an actively enrolling FDA Pivotal Study, while Dx2 has delivered the first clinical evidence that BlinkLab’s underlying technology can extend beyond ASD, generating encouraging European ADHD case-control results and establishing a defined path toward an FDA submission in 2027. Together with a materially strengthened balance sheet, these developments mark BlinkLab's evolution from a single-product, pre-clearance diagnostic story into a multi-indication platform, now advancing two distinct, large addressable markets rather than one.
BlinkLab has also advanced several important supporting workstreams since our last update, including an expanding international research footprint spanning Morocco, Ecuador and a ten-programme academic pipeline, and an A$17.5 million capital raise that has meaningfully de-risked near-term funding. Dx1's FDA Pivotal Study remains one of the most important near-term catalysts for BlinkLab, and, based on evidence from the Pilot Study to date, the platform appears capable of doing far more than diagnosing ASD.
European ADHD Results Validate a Second Major Commercial Vertical
BlinkLab's ADHD-focused Dx2 achieved 82% sensitivity and 83% specificity in a European case-control study of 208 children aged 6-17, the first external evidence that BlinkLab's core neurometric approach generalises beyond the condition it was originally built to diagnose. In our view, this is a materially bigger event than a simple pipeline update - ADHD's diagnosed population is several multiples (~5x) the size of ASD's, spans a far wider age range, and carries less social stigma, pointing to a larger, more accessible market than ASD alone. Dx2 now follows a defined regulatory pathway, with its own Pivotal Study running from Q1 to Q3 2027, and an FDA response on 510(k) clearance targeted for Q1 2028. Management's ambition extends further still, positioning Dx2 not just as a diagnostic aid but as a tool capable of monitoring treatment response over time, which, if validated, would shift BlinkLab toward a recurring-revenue model well beyond the one-off diagnostic economics.
Autism Programme Continues to De-Risk - On Track for FDA Clearance
Dx1 remains BlinkLab's most advanced and most important commercial asset, and it has continued to advance on essentially every front that matters. Dx1's 485-participant US Pilot Study delivered 83.7% sensitivity and 84.7% specificity, comfortably clear of the FDA's agreed >65% threshold and ahead of what BlinkLab's two FDA-cleared US competitors achieved in their own pivotal trials. BlinkLab has since converted that result into regulatory momentum, completing a ten-site US clinical network and enrolling the first participant into its FDA Pivotal Study, with a 510(k)-submission targeted by year-end 2026 and an FDA response on clearance targeted for 1Q 2027. In our view, the central risk has now shifted from whether the technology works to whether BlinkLab can execute this larger study at scale.
Growing Diagnostic Demand Supports BB1’s Long-Term Re-Rating Potential
We update our valuation for BB1 to $2.64 per share in the base case, representing ~291% upside, and to $3.49 per share in the upside case, representing ~416% upside, resulting in a midpoint Price/NAV of 0.22x. ASD and ADHD diagnosis in the US remains defined by chronic under-capacity, subjective assessment and multi-year waitlists. BlinkLab is now advancing two indications concurrently, each backed by clinical results that outperform existing FDA-cleared alternatives, giving it a rare shot at capturing two large markets. The US paediatric opportunity across both indications alone represents close to A$9.1 billion in the addressable market, based on our conservative estimates. With a research pipeline also testing extensions into paediatric and adult neurodevelopmental studies, we see meaningful further upside.